Anthony M. Insogna

Certain Post-Approval Activities to Support Submissions to the FDA Are Now Subject to Claims of Patent Infringement
Jonathan Berman,Anthony M. Insogna, September 22, 2011
On August 31, the Federal Circuit significantly restricted the scope of the "safe harbor" provision of 35 U.S.C. § 271(e)(1), which immunizes the use of patented inventions in connection with regulatory submissions to the Food and Drug Administration ("FDA"). Classen...

President Obama Proposes Reducing the Exclusivity Period of Brand-Name Biological Products
Jonathan Berman,Laura A. Coruzzi,Anthony M. Insogna, September 22, 2011
President Obama, in his new budget plan, proposes reducing the exclusivity period for brand-name biologics from 12 years to seven. The President would also limit the ability of manufacturers to obtain additional periods of exclusivity.

The 2011 Patent Reform Act
David B. Cochran,Thomas E. Friebel,Anthony M. Insogna,Ognjan V. Shentov,Peter G. Thurlow, September 22, 2011
The most significant changes to the U.S. patent law in more than 50 years have finally come to pass. The practice of U.S. patent law will never be the same. It took more than six years of Congressional debate for the U.S. Senate to pass the House version of the Leahy-Smith America Invents Act...